Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes ...
<span style="font-family: sans-serif , arial , helvetica;font-size: 11
<span style="font-family: sans-serif , arial , helvetica;font-size: 11
<span style="color: rgb(51,51,51);font-family: sans-serif , arial , helvetica;font-size: 11
<span style="color: rgb(51,51,51);font-family: sans-serif , arial , helvetica;font-size: 11
Ardelyx is a publicly traded commercial biopharmaceutical company fo...
Ardelyx is a publicly traded commercial biopharmaceutical company founded with a mission to discover, develop and c...
Ardelyx is a publicly traded commercial biopharmaceutical company founded with a mission to discover, develop...
Ardelyx is a publicly traded commercial biopharmaceutical company founded with a mission to discover, develop...
Ardelyx is a publicly traded commercial biopharmaceutical company founded with a mission to discover, develop and c...
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada.
Community Guidelines: https://rb.gy/07ltg3
